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Abstract:
Introduction: Stroke is the sudden onset of a neurologic deficit. It comes from a vascular
nreclranism.S5% are ischemic and l5%oare hemorrhagic. Ischemic defects with less than 3
hours, without any bleeding based on CT scan criteria, may benefit from thrombolltic
treatment with intravenous tissue plasminogen activator (tPA). tPA is currently the only
approved medical treatment fbr acute ischemic stroke" The airn of this study was to
evaiuate the tPA for the treatrnent of ischemic stroke by Health Technology' Assessment
(HTA) approach.
Methods: To evaluate the safety and efficacv dirnensions of the drug, systematic reviews
and meta-analysis studies that u'ere conducted to colrpare the clinical eff'ects of this drug
contpared tvtth the standard treatrnent ibr ischemrc stroke ri'ere used. the results were
evaluated r.rsing odds ratios. For the econonr.ic evaiuation. the \{arkov model was used to
simltlate the costs and rrulCorres of using tP^{ rn corrparison u'rth the standard treatment.
Results \\'ire anaLvzcd nsins ICER. For cthical and organizational evaluation, a
questlonnalre rncluding larious aspects of ethical and organizational issues was given to
tieurologists. Colrtent analysis u,as useci to examine the received responses.
Results: The rnortality rate of patients in the short term was higher in the tPA group, but in
the long teun, there was no significant difference betr'veen the two groups. The rate of
slmptomatic intracerebral hemorrhage within the first 7 days after treatment was higher in
the 
-eroup tPA. The patients with modified Rankin Scale (0-2) were ll1ore in the tPA group.
Economic evaluation was carried out from both the third party payer and the health system
perspective. ln both perspectives, ICER was identified as cost-effective with tPA treatment
with values of 274521942 and 308601702 Rials per QALY and located in the southeastern
and uortheastern regions of acceptability plane respectively, below the Threshold" In the
ethical evaluation, most of the elements were considered acceptable, but in the
organizational evaluation deficiencies were identified in the some hospitals for using tPA.
Discussion: Considering the results of safety studies, efficacy and cost-effectiveness of
tPA in the treatment of ischemic stroke in Iran, it seems reasonable to insure and apply it,
Infomration from ethical and organizational assessments suggested that policy makers,
given the high rates of the disease in the country, were planning and trying to identify the
early syrnptoms of the disease in the community to prevent, loss of golden time" Also
equipping the medical centers and neurology departn-rents to be more serious in their
agenda.
Ker n-ords: tissue type plasrninogen activator- acute ischemic stroke-Health Technology
A s se s sment- S afety-Effectiveness
